Shots:
The MHRA has approved Cytokinetics’ Myqorzo (aficamten) for the treatment of adults with symptomatic (NYHA, class II-III) oHCM
MHRA assessment was based on P-III (SEQUOIA-HCM) trial of Myqorzo (n=282), showing improved exercise capacity vs PBO at 24wks., with increased peak oxygen uptake by 1.8 vs 0 ml/kg/min
Additionally, NICE has recommended aficamten for eligible…
Introduction
PRIME (PRIority MEdicines)
EMA launched PRIME on March 07, 2016, to support the development of medicines targeting unmet medical needs. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients faster.
PRIME builds on the…
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it
The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019
PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it.
The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019.
PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it
The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019
PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where…

